Comparison of application of 2013 ACC/AHA guideline and 2011 European Society of Cardiology guideline for the management of dyslipidemias for primary prevention in a Turkish cohort.
OBJECTIVE
Atherosclerotic cardiovascular disease is a major global cause of death. The common approach in primary prevention of cardiovascular disease is to identify patients at high risk for cardiovascular disease. This article analyzes and compares the application of 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline and the 2011 European Society of Cardiology (ESC) guideline for the management of dyslipidemias for primary prevention in Turkish population.


METHODS
The study included 833 patients (482 women and 351 men). Risk scores were calculated according to both guidelines and indications for statin treatment were determined according to sex and age group. Variables are presented as mean±SD or median with interquartile range for continuous data and as proportions for categorical data. Variables were analyzed by unpaired t-test, Mann-Whitney U test, chi-square or Fischer's exact test as appropriate.


RESULTS
The ACC/AHA would suggest statin treatment in 415 patients out of 833 (49.5%), while ESC would recommend statin for 193 patients out of 833 (23.1%)(p<0.001). Statins would be recommended for 40.4% of women and 62.6% of men for primary prevention by the ACC/AHA, while this figure was 12% for women and 38.4% for men according to the ESC guideline (p<0.001 for both).


CONCLUSIONS
When compared to the ESC guideline, the ACC/AHA guideline suggests augmented statin treatment for primary prevention in Turkish population.
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey. yilmazmustafa2001@yahoo.com.
Mustafa
M
Yılmaz
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey.
İlyas
İ
Atar
Department of Cardiology, Nizip State Hospital; Gaziantep-Turkey.
Senem
S
Hasırcı
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey.
Kadirhan
K
Akyol
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey.
Abdullah
A
Tekin
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey.
Emir
E
Karaçağlar
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey.
Orçun
O
Çiftçi
Department of Cardiology, Faculty of Medicine, Başkent University; Adana-Turkey.
Haldun
H
Müderrisoğlu
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D050171:Dyslipidemias / Q000517:prevention & control*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000600:supply & distribution; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D012307:Risk Factors; D012955:Societies, Medical; D014421:Turkey
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
Int J Epidemiol. 2001 Jun;30(3):427-32; discussion 433-4
11416056
Eur Heart J. 2011 Jul;32(14):1769-818
21712404
Eur Heart J. 2014 Nov 7;35(42):2950-9
25139896
BMC Public Health. 2006 Oct 18;6:255
17049075
JAMA. 2014 Apr 9;311(14):1416-23
24681960
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
24239923
Eur Heart J. 2014 Mar;35(9):537-9
24204012
JAMA. 2001 May 16;285(19):2486-97
11368702
Eur Heart J. 2012 Jul;33(13):1635-701
22555213
Eur Heart J. 2014 Apr;35(15):958-9
24569030
Circulation. 1994 Jul;90(1):583-612
8026046
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004816
23440795
Lancet. 2012 Aug 11;380(9841):581-90
22607822
Lancet. 2007 Dec 15;370(9604):2054-62
18063025
Circulation. 2014 Jan 21;129(3):399-410
24446411